Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.

ABSTRACT:

Importance

β-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer disease.

Objective

To perform post hoc analyses of amyloid reduction after donanemab treatment and assess its association with tau pathology and clinical measures.

Design, setting, and participants

The Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) was a phase 2, placebo-controlled, randomized clinical trial conducted from December 18, 2017, to December 4, 2020, with a double-blind period of up to 76 weeks and a 48-week follow-up period. The study was conducted at 56 centers in the US and Canada. Enrolled were participants from 60 to 85 years of age with gradual and progressive change in memory function for 6 months or more, earl

SUBMITTER: Shcherbinin S 

PROVIDER: S-EPMC9468959 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature